Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

MarketBeat • Aug 7, 2026

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Zacks Investment Research • Aug 7, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

GlobeNewsWire • Aug 7, 2026

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.

GlobeNewsWire • Aug 6, 2026

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.

GlobeNewsWire • Jul 30, 2026

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Zacks Investment Research • Jul 20, 2026

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

Zacks Investment Research • Jul 9, 2026

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

The Motley Fool • Jul 8, 2026